Pharmacological management of human respiratory syncytial virus infection

Simple item page
dc.catalogadorpau
dc.contributor.authorKalergis, Alexis M.
dc.contributor.authorJorge A. Soto
dc.contributor.authorNicolás M. S. Gálvez
dc.contributor.authorCatalina A. Andrade
dc.contributor.authorAyleen Fernandez
dc.contributor.authorKaren Bohmwald
dc.contributor.authorBueno Ramirez, Susan Marcela
dc.date.accessioned2024-03-08T19:00:12Z
dc.date.available2024-03-08T19:00:12Z
dc.date.issued2020
dc.description.abstractIntroduction: Human respiratory syncytial virus (hRSV) is the primary viral cause of respiratory diseases, leading to bronchiolitis and pneumonia in vulnerable populations. The only current treatment against this virus is palliative, and no efficient and specific vaccine against this pathogen is available. Areas covered: The authors describe the disease symptoms caused by hRSV, the economic and social impact of this infection worldwide, and how this infection can be modulated using pharmacological treatments, preventing and limiting its dissemination. The authors discuss the use of antibodies as prophylactic tools -such as palivizumab- and the use of nonspecific drugs to decrease the symptoms associated with the infection -such as bronchodilators, corticoids, and antivirals. They also discuss current vaccine candidates, new prophylactic treatments, and new antivirals options, which are currently being tested. Expert opinion: Today, many researchers are focused on developing different strategies to modulate the symptoms induced by hRSV. However, to achieve this, understanding how current treatments are working and their shortcomings needs to be further elucidated.
dc.format.extent10 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1080/14656566.2020.1806821
dc.identifier.urihttps://doi.org/10.1080/14656566.2020.1806821
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/84315
dc.information.autorucFacultad de Ciencias Biológicas; Bueno Ramirez, Susan Marcela; 0000-0002-7551-8088; 113541
dc.issue.numero18
dc.language.isoen
dc.nota.accesoContenido completo
dc.revistaExpert Opinion on Pharmacotherapy
dc.rightsacceso restringido
dc.titlePharmacological management of human respiratory syncytial virus infection
dc.typeartículo
dc.volumen21
sipa.codpersvinculados113541
sipa.trazabilidadORCID;2024-01-15
Files
Collections
Artículos de revistas